Trials / Enrolling By Invitation
Enrolling By InvitationNCT05563259
Cognitive Assessment and Brain Function Evaluation in Patients With Non-alcoholic Fatty Liver Disease
The Cross-sectional and Longitudinal Study of Relationship Between Non-alcoholic Fatty Liver Disease and Cognitive Impairment
- Status
- Enrolling By Invitation
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Yan Bi · Academic / Other
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to explore the relationship between Non-alcoholic fatty liver disease and cognitive impairment and evaluate the effect of metabolic surgery or lifestyle intervention on cognition.
Detailed description
Previous research has shown that Non-alcoholic fatty liver disease (NAFLD) is associated with an increased risk of cognitive impairment. Even though there are many noninvasive tests available, a liver biopsy is still required for the accurate diagnosis of NAFLD. However, there are now few studies on cognitive function in patients with NAFLD based on pathological diagnosis. On one hand, in the cross-sectional study, biometric measurements, cognitive assessment, magnetic resonance imaging (MRI) results are analysed to explore the differences among control subjects and NAFLD patients undergoing liver biopsy. One the other hand, in the longitudinal study, changes in cognitive scales and MRI results in NAFLD patients both at baseline and 12-48 months after intervention are collected to investigate whether surgical intervention and weight control benefit brain function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Cognitive assessment, functional magnetic resonance imaging | Our study investigated cognitive function, MRI measures of brain structure and activation in patients undergoing liver biopsy. We aimed to evaluate the changes of cognition during the process of NAFLD and explore the association between brain alterations and cognition. |
Timeline
- Start date
- 2020-05-01
- Primary completion
- 2022-09-30
- Completion
- 2025-09-01
- First posted
- 2022-10-03
- Last updated
- 2024-06-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05563259. Inclusion in this directory is not an endorsement.